Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence

References

• European Medicines Agency. European public assessment reports - biosimilars [Internet]. cited 2017 Sep 28. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit
   Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun 10;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Biggioggero M, Danova M, Genovese U, et al. The challenging definition of naïve patient for biological drug use. Autoimmun Rev. 2015;14:543–546.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825–2833.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210–221.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–178.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44(7):774–781.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency; European Commission. Biosimilars in the EU - Information guide for health care professionals [Internet]. 2017. cited 2017 Sep 28. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
   Google Scholar
• Pineda C, Caballero-Uribe CV, de Oliveira MG, et al. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol. 2015;34(4):635–640.
   PubMed Web of Science ®Google Scholar
• Nagai S, Yanagihara R, Kishioka Y. Japanese regulatory authority’s perspective on biosimilars. Lancet Oncol. 2015 Mar;16(3):e101.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Chen B, Wyatt MD, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014;15(13):e594–605.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Public Health Service Act. Title III - General Powers and Duties of Public Health Service. USA. Section 351(i)(3) [Internet]. 2013. cited 2017 Sep 28. Available from: http://legcounsel.house.gov/Comps/PHSA_CMD.pdf
   Google Scholar
• Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product - guidance for industry [Internet]. 2017. cited 2017 Sep 28. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf
   Google Scholar
• Indiana State. Senate enrolled act. Bill number 262 [Internet]. 2014. [Cited 2017 Nov 26]. Available from: http://iga.in.gov/static-documents/b/3/b/f/b3bf9b4c/SB0262.04.ENRS.pdf
   Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products [Internet]. 2014. cited 2017 Sep 28. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
   Google Scholar
• GABI Journal. Biosimilar policies in Spain [Internet]. 2013. cited 2017 Sep 28. Available from: http://gabi-journal.net/news/biosimilar-policies-in-spain
   Google Scholar
• Italian Medicines Agency. Position Paper sui Farmaci Biosimilari [Internet]. 2013. cited 2016 Aug 4. Available from: http://www.agenziafarmaco.gov.it/sites/default/files/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI.pdf
   Google Scholar
• GABI Journal. France to allow biosimilars substitution [Internet]. 2014. cited 2017 Sep 28. Available from: www.gabionline.net/Policies-Legislation/France-to-allow-biosimilars-substitution
   Google Scholar
• FederSanitàAnci. Per creare cultura su un approccio corretto dei farmaci biosimilari. Position Paper [Internet]. 2015. cited 2017 Sep 28. Available from: http://www.federsanita.it/
   Google Scholar
• European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins [Internet]. 2007. cited 2017 May 12. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf
   Google Scholar
• Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. Bio Drugs. 2017;31(4):299–316.
   Google Scholar
• Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol. 2008;4(12):1537–1549.
   PubMed Web of Science ®Google Scholar
• Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008;20(4):431–435.
   PubMed Web of Science ®Google Scholar
• Cai X-Y, Thomas J, Cullen C, et al. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development. Bioanalysis. 2012 Sep;4(17):2169–2177.
   PubMed Web of Science ®Google Scholar
• Kurki P, Van Aerts L, Wolff-Holz E, et al. Interchangeability of biosimilars: a European perspective. Bio Drugs. 2017;83–91.
   Google Scholar
• Vezér B, Buzás Z, Sebeszta M, et al. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin. 2016;32(5):829–834.
   PubMed Web of Science ®Google Scholar
• Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005 Jun;67(6):2346–2353.
   PubMed Web of Science ®Google Scholar
• Pivot X, Gligorov J, Müller V, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol Off J Eur Soc Med Oncol. 2014 Oct;25(10):1979–1987.
   PubMed Web of Science ®Google Scholar
• Więcek A, Ahmed I, Scigalla P, et al. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: posthoc analysis. Adv Ther. 2010;27(12):941–952.
   PubMed Web of Science ®Google Scholar
• Romer T, Zabransky M, Walczak M, et al. Effect of switching recombinant human growth hormone: comparative analysis of phase 3 clinical data. Biol Ther. 2011;1:5.
   PubMedGoogle Scholar
• Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346–354.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76(2):355–363.
   PubMed Web of Science ®Google Scholar
• Buer LCT, Moum BA, Cvancarova M, et al. Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohn’s Colitis. 2017;11(3):297–304.
   Google Scholar
• Sieczkowska J, Jarzębicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis. 2016;10(2):127–132.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Thaçi D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928–938.
   PubMed Web of Science ®Google Scholar
• Park W, Suh CH, Shim SC, et al. Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: results of a 56-week open-label study in patients with rheumatoid arthritis. Bio Drugs. 2017;31(4):369–377.
   Google Scholar
• Ingrasciotta Y, Giorgianni F, Bolcato J, et al. How much are biosimilars used in clinical practice? A retrospective Italian population-based study of erythropoiesis-stimulating agents in the years 2009-2013. Bio Drugs. 2015;29(4):275–284.
   Google Scholar
• D’Amore C, Da Cas R, Rossi M, et al. Switching between epoetins: a practice in support of biosimilar use. Bio Drugs. 2016;30(1):27–32.
   Google Scholar
• Marcianò I, Ingrasciotta Y, Giorgianni F, et al. How did the introduction of biosimilar filgrastim influence the prescribing pattern of granulocyte colony-stimulating factors? Results from a multicentre, population-based study, from five Italian centres in the years 2009-2014. Bio Drugs. 2016;30(4):295–306.
   Google Scholar
• Flodmark C-E, Lilja K, Woehling H, et al. Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience From Sweden. Biol Ther. 2013;3:35–43.
   PubMedGoogle Scholar
• Rashid N, Saenger P, Wu Y-L, et al. Switching to Omnitrope(registered trademark) from other recombinant human growth hormone therapies: a retrospective study in an integrated healthcare system. Biol Ther. 2014;4(1–2):27–39.
   PubMedGoogle Scholar
• Borras Perez MV, Kristrom B, Romer T, et al. Ten years of clinical experience with biosimilar human growth hormone: a review of safety data. Drug Des Devel Ther. 2017;11:1497–1503.
   PubMed Web of Science ®Google Scholar
• Hörbrand F, Bramlage P, Fischaleck J, et al. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol. 2013;69(4):929–936.
   PubMed Web of Science ®Google Scholar
• Minutolo R, Bolasco P, Chiodini P, et al. Effectiveness of switch to Erythropoiesis-Stimulating Agent (ESA) biosimilars versus maintenance of ESA originators in the real-life setting: matched-control study in hemodialysis patients. Clin Drug Investig. 2017;37(10):1–9.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Sørensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426–1431.
   PubMed Web of Science ®Google Scholar
• Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15(12):1677–1683.
   PubMed Web of Science ®Google Scholar
• Becciolini A, Raimondo MG, Crotti C, et al. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. Drug Des Devel Ther. 2017;11:1969–1978.
   PubMed Web of Science ®Google Scholar
• Moots R, Azevedo V, Coindreau JL, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep. 2017;19(6).
   PubMed Web of Science ®Google Scholar
• Inotai A, Prins CPJ, Csanádi M, et al. Is there a reason for concern or is it just hype?–A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther. 2017;17(8):915–926.
   PubMed Web of Science ®Google Scholar
• Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12(11):1473–1485.
   PubMed Web of Science ®Google Scholar
• Loiacono C, Sgroi C, Coppolino S, et al. How much are biosimilars used in southern Italy?: A retrospective analysis of epoetin utilization in the local health unit of Messina in the years 20102011. Bio Drugs. 2012;26(2):113–120.
   Google Scholar